Myrbetriq: first beta-3 agonist for overactive bladder coming soonMedication is the first in a new class of drugs used to manage overactive bladder. Patients on androgen-deprivation therapy receive inadequate bone health careMost lack basic information about bone health, are not receiving appropriate screening, and are not engaging in appropriate healthy bone behaviours, study finds. Beware the shrinking penis Researchers raise awareness of a little-known side-effect of prostate cancer therapy From bikes to vibrators: The many ways to hurt the genitals Men suffer most such injuries, but sex toy incidents more common in women What’s best for incontinence? Updated urinary incontinence guidelines Update provides concise approach to the evaluation, management of urinary incontinence in adults. Inlyta for metastatic renal cell carcinoma Drug is the fourth kinase inhibitor to be approved for treatment of metastatic renal cell carcinoma in Canada. Cialis approved for benign prostatic hyperplasia Tadalafil, a phosphodiesterase type 5 inhibitor, was formerly indicated only for the treatment of ED in men. Cranberry confirmed as UTI fighter Up yours: Montreal urologist helping men check their prostate health First Previous 12 13 14 15 16 Next Last
